NeuroSense Therapeutics is a clinical-stage biotech company focused on discovering and developing treatments for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's. Their lead product candidate, PrimeC, is an oral therapy for ALS. They also have preclinical pipeline candidates for Parkinson's and Alzheimer's. Founded in 2017 and headquartered in Herzliya, Israel, NeuroSense is currently conducting a Phase 2b clinical study for ALS treatment.